drugset / Trial / NCT03758339

A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

NCT03758339

Phase 1 Completed 8 enrolled Cascadian Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will look at how a drug (tucatinib) leaves the body and what happens to tucatinib while it is still in the body. Healthy participants will get one dose of tucatinib by mouth. Patients will be monitored for 8-14 days after they take the dose of tucatinib.

Timeline

Start
2017-12-30
Primary completion
2018-01-30
Completion
2018-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucatinib Small molecule 300 mg Oral

Indications

No indication recorded.